Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand MA, Nusshag C, Bullinger L, Schrezenmeier JF, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild MJGT, Schmiedel S, Addo MM, Herth F, Kreuter M, Tepasse PR, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad MA, Schimanski CC, Celik C, Pohle T, Ruhe M, Kern WV, Schmitt A, Lorenz HM, Souto-Carneiro M, Gaeddert M, Halama N, Meuer S, Kräusslich HG, Müller B, Schnitzler P, Parthé S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk RF, Müller-Tidow C. Denkinger CM, et al. Among authors: witzke o. Nat Cancer. 2023 Jan;4(1):96-107. doi: 10.1038/s43018-022-00503-w. Epub 2022 Dec 29. Nat Cancer. 2023. PMID: 36581734 Free PMC article. Clinical Trial.
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, Krist L, Lemhöfer C, Lieb W, Lorenz-Depiereux B, Mikolajczyk R, Montellano FA, Reese JP, Schreiber S, Skoetz N, Störk S, Vehreschild JJ, Witzenrath M, Grill E; NAPKON Study Group. Shi Y, et al. Infection. 2023 Dec;51(6):1679-1694. doi: 10.1007/s15010-023-02043-6. Epub 2023 May 25. Infection. 2023. PMID: 37231313 Free PMC article.
Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M, Brochhagen L, Alt M, Otte M, Thümmler L, van de Sand L, Kraiselburd I, Thomas A, Gosch J, Braß P, Ciesek S, Widera M, Dolff S, Dittmer U, Witzke O, Meyer F, Lindemann M, Schönfeld A, Rohn H, Krawczyk A. Bormann M, et al. Among authors: witzke o. Front Immunol. 2023 Jul 13;14:1150667. doi: 10.3389/fimmu.2023.1150667. eCollection 2023. Front Immunol. 2023. PMID: 37520539 Free PMC article.
Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents.
Paniskaki K, Goretzki S, Anft M, Konik MJ, Lechtenberg K, Vogl M, Meister TL, Pfaender S, Zettler M, Jäger J, Dolff S, Westhoff TH, Rohn H, Felderhoff-Mueser U, Stervbo U, Witzke O, Dohna-Schwake C, Babel N. Paniskaki K, et al. Among authors: witzke o. BMC Infect Dis. 2023 Nov 22;23(1):818. doi: 10.1186/s12879-023-08805-9. BMC Infect Dis. 2023. PMID: 37993788 Free PMC article.
Increased SARS-CoV-2 reactive low avidity T cells producing inflammatory cytokines in pediatric post-acute COVID-19 sequelae (PASC).
Paniskaki K, Goretzki S, Anft M, Konik MJ, Meister TL, Pfaender S, Lechtenberg K, Vogl M, Dogan B, Dolff S, Westhoff TH, Rohn H, Felderhoff-Mueser U, Stervbo U, Witzke O, Dohna-Schwake C, Babel N. Paniskaki K, et al. Among authors: witzke o. Pediatr Allergy Immunol. 2023 Dec;34(12):e14060. doi: 10.1111/pai.14060. Pediatr Allergy Immunol. 2023. PMID: 38146118
Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants.
Thümmler L, Beckmann N, Sehl C, Soddemann M, Braß P, Bormann M, Brochhagen L, Elsner C, Hoertel N, Cougoule C, Ciesek S, Widera M, Dittmer U, Lindemann M, Horn PA, Witzke O, Kadow S, Kamler M, Gulbins E, Becker KA, Krawczyk A. Thümmler L, et al. Among authors: witzke o. Viruses. 2024 Mar 30;16(4):545. doi: 10.3390/v16040545. Viruses. 2024. PMID: 38675888 Free PMC article.
Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination.
Paniskaki K, Konik MJ, Anft M, Meister TL, Marheinecke C, Pfaender S, Jäger J, Krawczyk A, Zettler M, Dolff S, Westhoff TH, Rohn H, Stervbo U, Witzke O, Babel N. Paniskaki K, et al. Among authors: witzke o. Front Immunol. 2022 Oct 31;13:1031254. doi: 10.3389/fimmu.2022.1031254. eCollection 2022. Front Immunol. 2022. PMID: 36389833 Free PMC article.
Patients with SARS-CoV-2-Induced Viral Sepsis Simultaneously Show Immune Activation, Impaired Immune Function and a Procoagulatory Disease State.
Limmer A, Engler A, Kattner S, Gregorius J, Pattberg KT, Schulz R, Schwab J, Roth J, Vogl T, Krawczyk A, Witzke O, Zelinskyy G, Dittmer U, Brenner T, Berger MM. Limmer A, et al. Among authors: witzke o. Vaccines (Basel). 2023 Feb 13;11(2):435. doi: 10.3390/vaccines11020435. Vaccines (Basel). 2023. PMID: 36851312 Free PMC article.
Low avidity circulating SARS-CoV-2 reactive CD8+ T cells with proinflammatory TEMRA phenotype are associated with post-acute sequelae of COVID-19.
Paniskaki K, Konik MJ, Anft M, Heidecke H, Meister TL, Pfaender S, Krawczyk A, Zettler M, Jäger J, Gaeckler A, Dolff S, Westhoff TH, Rohn H, Stervbo U, Scheibenbogen C, Witzke O, Babel N. Paniskaki K, et al. Among authors: witzke o. Front Microbiol. 2023 Jun 2;14:1196721. doi: 10.3389/fmicb.2023.1196721. eCollection 2023. Front Microbiol. 2023. PMID: 37333646 Free PMC article.
378 results